A study carried out shows the benefits of once-daily, 24-hour basal insulin Lantus when compared to twice-daily insulin detemir.
Sanofi-aventis announced results of a head-to-head study providing further evidence on the efficacy of once-daily, 24-hour basal insulin Lantus compared to twice-daily insulin detemir.
The study was presented during the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna.
In the head-to-head, randomised, non-inferiority controlled clinical trial of 964 patients, patients taking Lantus required an average daily dose of 43.5 units to achieve the primary endpoint of HbA1c below 7% without symptomatic hypoglycaemia compared to patients on insulin detemir, who received 76.5 units – an increase of 76%.
Despite lower doses of insulin in the glargine group, Lantus once-daily and insulin detemir twice-daily resulted in similar improvements in glycemic control (HbA1c) and a similar risk of hypoglycaemia. Patients in the Lantus arm of the study also achieved significantly lower fasting blood glucose.
In the study, patients taking Lantus once-daily reported a significantly greater treatment satisfaction over insulin detemir twice-daily, with over 50% less drop-outs. Whilst a similar rate of overall hypoglycaemia and nocturnal hypoglycaemia was observed in both arms, patients on Lantus once-daily experienced less daytime hypoglycaemia as compared to insulin detemir. Patients on insulin detemir experienced less weight gain.
To find out more, please click on the link below.
